Sign in
CompletedNo phase

Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia

Key facts

Who runs it
Masonic Cancer Center, University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Status
Completed
People taking part
61 people enrolled
Started
10 Jan 2015
Ended
11 Mar 2025
Type of study
Interventional, 5 groups
Treatments tested
  • Alemtuzumab
  • Fludarabine
  • Cyclophosphamide
  • Total Body Irradiation
  • Stem Cell Transplant
  • Anti-thymocyte globulin
Record updated
8 May 2025

Who can take part

Age
0 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (18)Hide the full registry criteria

Who can take part

  • Aged 0 - 70 years
  • Acceptable hematopoeitic stem cell donor
  • Dyskeratosis Congenita (DC) with evidence of BM failure defined as:; requirement for red blood cell and/or platelet transfusions or; requirement for G-CSF or GM-CSF or erythropoietin or; refractory cytopenias having one of the following three; platelets <50,000/uL or transfusion dependent; absolute neutrophil count <500/uL without hematopoietic growth factor support; hemoglobin <9g/uL or transfusion dependent
  • Diagnosis of DC with a triad of mucocutaneous features:; oral leukoplakia; nail dystrophy; abnormal reticular skin hyperpigmentation, or
  • Diagnosis of DC with one of the following:; short telomeres (under a research study); mutation in telomerase holoenzyme (DKC1, TERT, TERC, NOP10, NHP2, TCAB1); mutation in shelterin complex (TINF2); mutation in telomere-capping complex (CTC1)
  • Severe Aplastic Anemia (SAA) primary transplant with evidence of BM failure:; Refractory cytopenia defined by bone marrow cellularity <50% (with < 30% residual hematopoietic cells)
  • Diagnosis of SAA with refractory cytopenias having one of the following three:; platelets <20,000/uL or transfusion dependent; absolute neutrophil count <500/uL without hematopoietic growth factor support; absolute reticulocyte count <20,000/uL
  • Severe Aplastic Anemia (SAA) requiring a 2nd transplant; Graft failure as defined by blood/marrow chimerism of < 5%
  • Early myelodysplastic features
  • With or without clonal cytogenetic abnormalities
  • Adequate organ function defined as:; cardiac: left ventricular ejection fraction ≥ 35% with no evidence of decompensated heart failure; pulmonary: DLCO ≥30% predicted, no supplemental oxygen requirement; renal: Glomerular filtration rate (GFR) ≥30% predicted
  • Voluntary written consent

Who cannot take part

  • Prior radiation therapy (applies to SAA patients only)
  • Acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on biopsy
  • Uncontrolled infection
  • Pregnant or lactating
  • Diagnosis of Fanconi anemia based on DEB
  • Diagnosis of dyskeratosis congenita with advanced MDS or acute myeloid leukemia with >30% blasts

Where in United States

  • University of Minnesota Medical Center, FairviewMinneapolis, United States

About the trial

What the trial wants to find out

Fludarabine-based preparative regimen followed by an allogeneic hematopoietic stem cell transplant using related or unrelated donor in persons 0-70 years of age diagnosed with dyskeratosis congenita or severe aplastic anemia who have bone marrow failure characterized by a requirement for red blood cell and platelet transfusions. Three different preparative regimens are included based on disease and donor type.

The 5 groups in the trial

  • Arm A Dyskeratosis Congenita (DKC) (non-haploidentical donor)Treatment being tested

    Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, followed by stem cell transplant for the treatment of dyskeratosis congenita.

    Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, and Stem Cell Transplant

  • Arm B: Severe Aplastic Anemia (SAA ) (non-matched related, non-haploidentical donor)Treatment being tested

    Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.

    Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin

  • Arm C: Severe Aplastic Anemia (matched related donor)Treatment being tested

    Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.

    Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin

  • Arm D: Dyskeratosis Congenita (DKC), PTCy platformTreatment being tested

    Fludarabine based preparative regimen, including alemtuzumab, cyclophosphamide, fludarabine, followed by stem cell transplant for the treatment of dyskeratosis congenita.

    Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, and Stem Cell Transplant

  • Arm E: Severe Aplastic Anemia (SAA), PTCy platformTreatment being tested

    Fludarabine based preparative regimen which includes: cyclophosphamide, fludarabine, rabbit ATG and total body irradiation. Followed by stem cell transplant.

    Treatment: Alemtuzumab, Fludarabine, Cyclophosphamide, Total Body Irradiation, Stem Cell Transplant, and Anti-thymocyte globulin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
8 May 2025